LLY stock forecast, quote, news & analysis

Key Takeaways

• Eli Lilly shares pulled back roughly 5% from early July all-time highs near $1,249, closing at $1,148.84 on July 31, as investors position ahead of the August 5 Q2 2026 earnings report.
• The core GLP-1 franchise — Mounjaro and Zepbound — generated $12.82 billion in combined Q1 revenue, about 65% of total sales, and remains the central driver of the investment thesis.
• Foundayo, Lilly's newly launched oral obesity pill, faces early prescription headwinds and intense competition from Novo Nordisk's oral Wegovy.
• Novo Nordisk filed a federal lawsuit in July alleging false advertising in Lilly's comparative drug campaigns, adding legal uncertainty to the competitive narrative.
• Wall Street remains broadly bullish, with a consensus Moderate Buy rating and an average price target of approximately $1,284 — though several firms have raised targets above $1,400.

Current Market Snapshot

Eli Lilly and Company (LLY) enters August 2026 trading near $1,149 after retreating from its all-time closing high of $1,235.56 set on July 7. The stock is hovering just above its 50-day moving average of roughly $1,151, a closely watched technical level that has provided support during prior pullbacks. The decline of approximately 5% over the trailing 30 days reflects a combination of profit-taking after a strong run, pre-earnings positioning, and emerging competitive and legal crosscurrents in the obesity drug market. With a market capitalization near $1.09 trillion and a forward price-to-earnings ratio around 41, LLY trades at a premium that leaves limited room for disappointment when it reports second-quarter results on August 5.

Eli Lilly (LLY) Business Overview and Competitive Position

Eli Lilly is a 150-year-old global pharmaceutical company headquartered in Indianapolis, Indiana, with a diversified portfolio spanning diabetes, obesity, oncology, immunology, and neuroscience. The company's modern growth story is anchored by its GLP-1 receptor agonist franchise: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (tirzepatide) for chronic weight management. Together, these two injectable therapies have reshaped the cardiometabolic treatment landscape and propelled Lilly to the forefront of the global obesity market, where it holds an estimated 60% revenue share against primary rival Novo Nordisk. Beyond GLP-1 therapies, Lilly's pipeline includes Kisunla for Alzheimer's disease, Jaypirca in oncology, and the next-generation obesity candidate retatrutide, which recently completed Phase 3 trials. The company has committed roughly $55 billion to U.S. manufacturing capacity to meet surging demand.

Recent Developments Driving LLY

Several significant events have shaped investor sentiment over the past 30 days. On July 16, Lilly announced the acquisition of AtaiBeckley for up to $3.8 billion, extending its reach into psychedelic-based treatments for depression — a signal that management is actively diversifying the pipeline beyond metabolic disease. On July 30, Lilly and contract manufacturer Resilience unveiled a $750 million investment to expand U.S. production capacity for injectable devices, reinforcing confidence in sustained long-term demand. On the competitive front, Novo Nordisk filed a federal lawsuit on July 21 alleging that Lilly's advertising for Zepbound and Mounjaro uses outdated clinical comparisons to misleadingly claim superiority, and sought a preliminary injunction on July 24. Lilly has denied wrongdoing and stands by its SURMOUNT-5 trial data. Meanwhile, prescription data from IQVIA indicated that Foundayo, Lilly's oral GLP-1 pill launched in April, has posted flat weekly prescriptions for several weeks, trailing the launch trajectory of Novo Nordisk's oral Wegovy. On the policy side, the Medicare GLP-1 Bridge program took effect July 1, lowering copays for eligible Part D beneficiaries to $50 per month through 2027 — a structural tailwind for the entire obesity treatment category.

Trending AI Robots

For traders seeking data-driven approaches to navigate volatile markets, Tickeron's Trending AI Robots page offers a curated window into hundreds of AI-powered trading bots that actively trade thousands of tickers. The platform highlights only the top-performing and most relevant bots in this section, allowing users to quickly identify strategies aligned with current market conditions. Bots vary by trading style, time horizon, and performance metrics — ranging from short-term momentum strategies to longer-term trend-following models — making it easier to find an approach that matches individual goals. Exploring the Trending AI Robots page can help investors discover systematic tools designed to complement their own research process.

2026 Outlook and What Investors Should Watch

The August 5 earnings report is the most immediate catalyst. Consensus estimates call for approximately $20.5 billion in revenue and $6.06 in earnings per share, though the market's true focus will be on management's full-year guidance — currently set at $82 billion to $85 billion in revenue — and any commentary on Foundayo's commercial trajectory. Beyond earnings, investors should monitor the progression of the Novo Nordisk advertising lawsuit, which could escalate into a preliminary injunction ruling affecting Lilly's marketing campaigns. On the competitive front, Viking Therapeutics plans to advance its oral GLP-1 candidate VK2735 into Phase 3 trials in Q4 2026, while Structure Therapeutics is expected to initiate late-stage studies of aleniglipron in the second half of the year. Retatrutide Phase 3 data, pending release, represents another potential catalyst that could extend Lilly's obesity franchise leadership. Macroeconomic risks, including potential shifts in employer coverage of GLP-1 drugs and upcoming Medicare price negotiation outcomes, add layers of uncertainty that warrant close attention.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations